A retrospective analysis of 17 cholangiocarcinoma cases revealed FGFR2-3 alterations in 82.3% of archival tumour samples and 50% of DNA samples (4/5 SNVs, 1/2 amplifications, and 5/13 fusions) (91). Here, FGFR2 is linked to neoplasm.